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Introduction
• Enhanced recovery after surgery refers to an optimization of preoperative, intraoperative, 
and postoperative care via a multidisciplinary team and multi-modal approach 
– E.g. Earlier removal of NG tube, reduced length of stay (LOS)
• A reduced LOS reduces time to adjuvant therapy (TTAT), which has been shown to improve 
patient outcomes and cost savings per patient ($3010 for colorectal and $7020 for pancreas 
surgery)
• However, readmission rate (RR) were found to be higher, particularly in patients with renal 
insufficiency, sepsis, pancreatic fistula, and delayed gastric emptying (DGE)
• Whipple Accelerated Recovery Pathway (WARP) trial at Jefferson aimed to reduce LOS to 5 
days (traditional = 7 days) without increasing rate of post-operative complications (POC)
– RESULT: Reduced TTAT and hospital costs 
Introduction
• Although WARP patient outcomes are promising, the program is limited to 
a highly selective group of patients. 
• From 2017, Jefferson began implementing the WARP pathway to all 
patients (previously categorized into WARP-ineligible and WARP-eligible), 
hoping to improve outcomes for a larger patient population 
• This study aimed to determine if WARP could be expanded to all patients 
undergoing PD by retrospectively comparing outcomes among previously 




– Purpose: To determine if WARP can be expanded to all risk-level patients
– Variables/outcome measures: POC (DGE and post-operative fistula 
[POP]), TTAT, patients initiating adjuvant therapy (PIAT), 30-day and 90-day 
mortality 
– Population: WARP-eligible vs. WARP-ineligible
• Hypothesis
– The WARP pathway can be expanded to all risk-level patients undergoing 
PD 
Approach & Results
• Study design & Population
– A single-institution retrospective review of 281 patients with benign (18.1%) and malignant (81.9%) 
disease who underwent PD between 2017-2020 
– Patients were categorized into WARP-eligible and WARP-ineligible groups based on the WARP 
inclusion criteria 
• High-risk patients were excluded à CHF, end-stage renal disease, O2-dependent COPD, hepatic cirrhosis,soft pancreatic gland 
texture
• Intervention
– Applying WARP to WARP-ineligible patients (162 patients, 57.7%) 
• Comparison group 
– Applying WARP to WARP-eligible patients (119 patients, 42.3%)
– Also compared to WARP patients from original WARP trial (results not included in this presentation)
• Outcome 
– LOS, TTAT, RR, POC (including delayed gastric emptying [DGE] and pancreatic fistula [POP], 30-day 
and 90-day mortality (and many, many more) 
• Data source, collection, and analysis
– Data source: EPIC, google drive (excel)
– Analysis: Univariate/multivariate logical regression analysis 
• Rationale for Approach
– EPIC contains all information pertaining to the outcome measures 
– Univariate/multivariate analysis approach to compare ≥ 1 variables
Approach & Results
Variable WARP-eligible (n = 119) WARP-ineligible (n = 162)  P-value 
LOS 5 6 <0.05
POC DGE (all 
grades)




RR 12.6% 23.5% <0.05




30-day mortality 2.5% 0.0% 0.04
90-day mortality 3.4% 1.2% 0.22
• Patient parameters
– E.g. Sex, Age, BMI
• Presurgical 
parameters




– E.g. Operative time, 
Est. blood loss, classic 
Whipple vs. PPPD
• Pathology parameters 




• Our results demonstrate lower LOS, median TTAT, PIAT, 30-day and 90-day mortality 
rates in both WARP-eligible and WARP-ineligible groups
– Would have been helpful to include existing LOS, TTAT, PIAT for non-WARP patients for 
comparison 
• However, there is still a significant difference in findings, especially for RR and POCs 
– Opens doors to future studies focusing on ways to reduce POC and RR while keeping LOS low 
• Nevertheless, our findings are consistent with current literature that enhanced recovery 
after surgery, focusing on reducing LOS along with other post-operative measures, is a 
significant contributor to positive patient outcomes 
Future Directions
• Comprehensive database à Several abstracts already submitted 
– Patients with G12V/R variant of pancreatic adenocarcinoma have significant greater survival  compared to 
patients with G12D – Collaboration with pathology department 
– Euglycemic diabetic ketoacidosis after PD may necessitate new or increased insulin at discharge and 
correlates with readmission due to postoperative pancreatic fistula.
• Future projects
– DGE rates at Jefferson vs. other institutions
– Significance of neoadjuvant therapy in patient outcomes and compliance/tolerability of adjuvant therapy 
– Use of perioperative beta-blockade to reduce cardiac complications 
– Opioid reduction during hospital stay 
All may contribute to explaining the discrepancies in RR and POCs in WARP-eligible and WARP-ineligible 
patients 
Acknowledgements
• Thank you to Dr. Krampitz, Dr. Bowne, and Shawnna for their 
support, encouragement, and commitment to this project  
and database
• Thank you to Cyrus and Hamza for being the architectures and 
backbone of this project 
• Thank you to Taylor and Cliff for working through the learning 
curve, obstacles, and time-consuming nature of this long, 
ongoing yet also valuable database! 
